Cancer Research Institute, University of California-San Francisco, 513 Parnassus Ave., San Francisco, CA 94143, USA.
Dis Model Mech. 2010 May-Jun;3(5-6):317-32. doi: 10.1242/dmm.003863. Epub 2010 Mar 11.
Innate regulatory networks within organs maintain tissue homeostasis and facilitate rapid responses to damage. We identified a novel pathway regulating vessel stability in tissues that involves matrix metalloproteinase 14 (MMP14) and transforming growth factor beta 1 (TGFbeta(1)). Whereas plasma proteins rapidly extravasate out of vasculature in wild-type mice following acute damage, short-term treatment of mice in vivo with a broad-spectrum metalloproteinase inhibitor, neutralizing antibodies to TGFbeta(1), or an activin-like kinase 5 (ALK5) inhibitor significantly enhanced vessel leakage. By contrast, in a mouse model of age-related dermal fibrosis, where MMP14 activity and TGFbeta bioavailability are chronically elevated, or in mice that ectopically express TGFbeta in the epidermis, cutaneous vessels are resistant to acute leakage. Characteristic responses to tissue damage are reinstated if the fibrotic mice are pretreated with metalloproteinase inhibitors or TGFbeta signaling antagonists. Neoplastic tissues, however, are in a constant state of tissue damage and exhibit altered hemodynamics owing to hyperleaky angiogenic vasculature. In two distinct transgenic mouse tumor models, inhibition of ALK5 further enhanced vascular leakage into the interstitium and facilitated increased delivery of high molecular weight compounds into premalignant tissue and tumors. Taken together, these data define a central pathway involving MMP14 and TGFbeta that mediates vessel stability and vascular response to tissue injury. Antagonists of this pathway could be therapeutically exploited to improve the delivery of therapeutics or molecular contrast agents into tissues where chronic damage or neoplastic disease limits their efficient delivery.
器官内的先天调节网络维持组织内稳态,并促进对损伤的快速反应。我们发现了一条新的途径来调节组织中血管的稳定性,该途径涉及基质金属蛋白酶 14(MMP14)和转化生长因子β1(TGFβ(1))。虽然在急性损伤后,野生型小鼠的血浆蛋白会迅速从血管中外渗,但在体内用广谱金属蛋白酶抑制剂、中和 TGFβ(1)的抗体或激活素样激酶 5(ALK5)抑制剂短期处理小鼠,会显著增强血管渗漏。相比之下,在皮肤纤维化的小鼠模型中,MMP14 活性和 TGFβ 生物利用度会持续升高,或者在表皮中异位表达 TGFβ 的小鼠中,皮肤血管对急性渗漏具有抗性。如果对纤维化小鼠进行金属蛋白酶抑制剂或 TGFβ 信号通路拮抗剂预处理,则可以恢复对组织损伤的特征性反应。然而,肿瘤组织由于高通透性的血管生成血管而处于持续的组织损伤和改变的血液动力学状态。在两种不同的转基因小鼠肿瘤模型中,抑制 ALK5 进一步增强了血管向间质的渗漏,并促进了高分子量化合物向癌前组织和肿瘤的输送。综上所述,这些数据定义了一条涉及 MMP14 和 TGFβ 的核心途径,该途径介导血管稳定性和血管对组织损伤的反应。该途径的拮抗剂可被用于治疗,以改善药物或分子对比剂在慢性损伤或肿瘤疾病限制其有效递送的组织中的递送。